Diurnal Group plc £20m fundraise success

We are very pleased to have acted as Nomad, Sole Broker and Sole Bookrunner for the successful £20m fundraising for Diurnal Group plc.

Diurnal is a European, UK-headquartered pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions.

The net proceeds of the fundraise will be used to progress the pivotal Phase 3 studies of Efmody® in the US through to registration in congenital adrenal hyperplasia (CAH) and the continued support of the evolution of the Group’s earlier stage pipeline.